Cost effectiveness of eptifibatide in acute coronary syndromes. An economic analysis of Western European patients enrolled in the PURSUIT trial | Zendy

Ruth E. Brown | Zendy; Robert Henderson | Zendy; Derk Koster | Zendy; John Hutton | Zendy; M. L. Simoons | Zendy

Open Access

Cost effectiveness of eptifibatide in acute coronary syndromes. An economic analysis of Western European patients enrolled in the PURSUIT trial

Author(s) -

Ruth E. Brown,

Robert Henderson,

Derk Koster,

John Hutton,

M. L. Simoons

Publication year - 2002

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.2001.2711

Subject(s) - medicine , euros , eptifibatide , myocardial infarction , acute coronary syndrome , cost–benefit analysis , cost effectiveness , emergency medicine , percutaneous coronary intervention , risk analysis (engineering) , humanities , philosophy , ecology , biology

To assess the direct medical costs and cost effectiveness of routine eptifibatide use amongst patients with unstable angina and myocardial infarction without persistent ST-segment elevation in the Western European subgroup of the PURSUIT trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research